Table 1. PET/CT derived pre- and posttherapeutic parameters as well as regressive changes and apoptosis of pretherapeutic biopsy specimens and posttherapeutic prostatectomy specimens of the therapy group and prostatectomy specimens of the control group.
| Parameters | Pretherapeutic | Posttherapeutic | Decrease in % | p-value |
|---|---|---|---|---|
| SUVmean | ||||
| median (mean) | 3.45 (3.43) | 2.28 (2.36) | 31.3 (30.4) | 0.004 |
| range | 2.84–3.87 | 1.67–4.07 | 26.4–56.9 | |
| SUVmax | ||||
| median (mean) | 7.13 (7.50) | 3.57 (3.68) | 52.1 (47.8) | 0.004 |
| range | 5.75–11.06 | 2.29–7.03 | 22.3–79.3 | |
| CT derived prostate volume (ml) | ||||
| median (mean) | 46.35 (54.30) | 29.56 (32.19) | 29.65 (35.88) | 0.005 |
| range | 31.05–90.25 | 16.61–65.65 | 22.03–55.90 | |
| Prostate specific antigen (ng/ml) | ||||
| median (mean) | 18.7 (40.9) | 0.68 (0.96) | 96.5 (92.9) | 0.003 |
| range | 1.1–260 | 0.3–2.4 | 70.5–99.5 | |
| Pretherapeutic1 | Posttherapeutic2 | Control group3 | p-value (*/**) | |
| TUNEL positive cells per HPF | ||||
| median (mean) | 0.6 (0.5) | 3.2 (4.3) | 1.35 (5.0) | 0.02/0.003 |
| range | 0–1.3 | 2.0–8.4 | 0.4–3.3 | |
| Regressive changes in % of whole tumor | ||||
| median (mean) | 0 | 40 (42) | 0 | |
| range | 0 | 15–80 | 0 |
1
pretherapeutic prostate biopsy
2
prostatectomy specimen of therapy group (neoadjuvant treatment)
3
prostatectomy specimen of control group (no neoadjuvant treament)
*
pretherapeutic vs. posttherapeutic
**
control group vs. posttherapeutic